Forte Biosciences (FBRX) Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Forte Biosciences (FBRX) Announces Pricing of $40 Million Public Offering of Common Stock at $28.50/sh
October 29, 2020 8:22 AM EDTForte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,403,509 shares of its common stock at a price to the public of $28.50 per share. In addition, Forte has granted to the underwriters a 30-day option to purchase up to an additional 210,526 shares of common stock... More
